Canagliflozin reduced kidney failure and CV events at 2.6 years in type 2 diabetes with chronic kidney disease.

Canagliflozin reduced kidney failure and CV events at 2.6 years in type 2 diabetes with chronic kidney disease. Ann Intern Med. 2019 Aug 20;171(4):JC15 Authors: Patel T PMID: 31426058 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/31426058?dopt=Abstract

Source: Annals of Internal Medicine - August 19, 2019 Category: Internal Medicine Authors: Patel T Tags: Ann Intern Med Source Type: research